immunoglobulin g2

Protein kinase G inhibitor-2 exhibits antibacterial, antiviral, and antitumor activities.

Compound 1059182-21-6 features a cyclic structure characterized by a nitrogen atom occupying an apex (corner) within the heterocycle. Its molecular scaffold integrates aromatic properties due to the presence of a conjugated system, while the inclusion of hydroxyl (-OH) groups confers reactive potential for subsequent modification. Additionally, a halogenated component, specifically a bromine atom, is attached to the aromatic ring, enhancing its propensity for undergoing further synthetic transformations.

FITC-εAhx-HHV-2 Envelope Glycoprotein G (561-578) is a fluorescein isothiocyanate (FITC)-labeled segment of the HHV-2 Envelope Glycoprotein G encompassing amino acids 561 to 578. This immunodominant region of glycoprotein G (gG-2) exhibits reactivity with all herpes simplex virus type 2 (HSV-2) sera [1].

4-Methyl-6,7,8,9-tetrahydro-2H-pyrano[3,2-g]quinolin-2-one is a useful organic compound for research related to life sciences and the catalog number is T66960.

2’-OMe-G(ibu) Phosphoramidite is a modified phosphoramidite monomer suitable for oligonucleotide synthesis.

2'-MOE-G(iBu)-3'-phosphoramidite is a Nucleoside Phosphoramidite;Nucleoside Derivative - 2'-Modified nucleoside;.

Rev 2'-O-MOE-G(iBu)-5'-amidite is a Nucleoside Phosphoramidite.

HHV-2 Envelope Glycoprotein G (552-574), an immunodominant region within glycoprotein G (gG-2), demonstrates reactivity with all herpes simplex (HSV-2) sera [1].

2'-O-Propargyl G(iBu)-3'-phosphoramidite is a Nucleoside Phosphoramidite; Nucleoside Derivative - 2'-Modified nucleoside.

3'-O-MOE-G(iBu)-2'-phosphoramidite is a Nucleoside Phosphoramidite.

3'-O-Me-G(iBu)-2'-phosphoramidite is a Nucleoside Phosphoramidite.

Denosumab is a monoclonal antibody given subcutaneously that inhibits osteoclast activity by targeting the RANK ligand

Insulin efsitora alfa (LY-3209590) is a selective insulin receptor (IR) agonist, featuring a fusion protein that combines human IR agonists with the crystallizable (Fc) domain of human immunoglobulin G2 (IgG2), and has a molecular weight of 64.1 kDa. This compound is well tolerated and shows promise for diabetes management [1].

Cirevetmab (ZTS-00521426), a caninized monoclonal antibody targeting Canis lupus familiaris TGFB1, is classified as an immunoglobulin G2-kappa. It functions as an immunomodulator [1].

Efbemalenograstim alfa (F 627) is a recombinant fusion protein consisting of a long-acting dimeric granulocyte colony-stimulating factor (G-CSF) with two human G-CSF molecules linked by a peptide to a human immunoglobulin G2 (hIgG2)-Fc fragment, designed to induce white blood cell production [1].